Preclinical News and Research

RSS

Teva third quarter 2012 net revenues increase 14% to $5.0 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended September 30, 2012.

1 Nov 2012

Omeros initiates enrollment in OMS824 Phase 1 trial for schizophrenia and Huntington's

Omeros Corporation today announced that the first subject has been enrolled in the Company's Phase 1 clinical trial evaluating OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program.

1 Nov 2012

Proposing standards and guidelines for Rett syndrome research

There is an urgent need for new drugs to treat Rett syndrome, a rare and severe neurological disease mainly affecting girls. A bottleneck in drug development for this syndrome is a lack of clarity at the level of preclinical research. Key researchers in this field now tackle this issue, proposing standards and guidelines for Rett syndrome research, in an Open Access review article published on Oct. 31, 2012 in Disease Models & Mechanisms (DMM).

1 Nov 2012

Isis announces preliminary data from ISIS-STAT3 Phase 1 study on cancer

Isis Pharmaceuticals, Inc. announced that preliminary data from the Phase 1 study of ISIS-STAT3Rx in patients with cancer were presented today at the Oligonucleotide Therapeutics Society in Boston.

1 Nov 2012

Integra Holdings, a biopharmaceutical holding company, announced by Yissum

Yissum Research and Development Company of the Hebrew University of Jerusalem, the technology transfer company of the Hebrew University, announced today the inception of its subsidiary, Integra Holdings, a holding company focusing on biopharmaceutical companies based on inventions of researchers from the Hebrew University.

31 Oct 2012

Development of children with ASD much like that of children without ASD at 6 months of age

The development of children with Autism Spectrum Disorder (ASD) is much like that of children without ASD at 6 months of age, but differs afterwards. That's the main finding of the largest prospective, longitudinal study to date comparing children with early and later diagnosis of ASD with children without ASD. The study appears in the journal Child Development and has implications for clinical work, public health, and policy.

31 Oct 2012

Study finds two distinct patterns of language, social and motor development in children with ASD

In the largest prospective study to date of children with early and later manifestation of autism spectrum disorders (ASD) compared to children without ASD, researchers found two distinct patterns of language, social and motor development in the children with ASD.

31 Oct 2012

BioCryst announces withdrawal of BCX5191 IND following discussion with FDA

BioCryst Pharmaceuticals, Inc. announced the withdrawal of its Investigational New Drug application (IND) for the antiviral nucleoside, BCX5191, following a discussion with the U.S. Food and Drug Administration (FDA).

31 Oct 2012

Study finds two distinct patterns of language, social and motor development in children with ASD

30 Oct 2012

Positive results from Celldex’s CDX-1401 Phase 1 study on solid tumors

Celldex Therapeutics, Inc. today announced positive results demonstrating promising clinical effects in a Phase 1 study of CDX-1401 in solid tumors in combination with the toll-like receptor (TLR) agonists resiquimod and/or Poly ICLC.

30 Oct 2012

Ultra-high performance SPECT systems announced by MILabs

MILabs, B.V. the Netherlands‐based innovator and manufacturer of pre‐clinical SPECT/PET/CT imaging devices announces the release of the Plus! Systems: the U‐SPECT+ and U‐SPECT+ /CT.

29 Oct 2012

Botanical treatment holds hope for triple-negative breast cancer

A unique formula made from medicinal mushrooms, traditional Chinese herbs and other natural ingredients inhibits aggressive, human triple-negative breast cancer and breast-to-lung metastasis in mice. This is the third peer-reviewed study to demonstrate the botanical formula's anticancer effects.

29 Oct 2012

SAGE announces purchase of The Journal of International Medical Research

SAGE has today announced the purchase of The Journal of International Medical Research from Field House Publishing LLP.

29 Oct 2012

Highlights from 25th European College of Neuropsychopharmacology Congress

In the course of the 25th ECNP Congress leading experts and five and a half thousand psychiatrists, neurologists, neuroscience researchers and public health professionals from over 90 different countries met from 13 to 17 October 2012 in Vienna, Austria, to celebrate ECNP´s 25-year anniversary and engage in groundbreaking debate.

26 Oct 2012

Thrasos completes $35 Million financing for development of THR-184 against AKI

Thrasos Therapeutics announced that it has completed a $35 Million (U.S.) financing for the development of THR-184, its lead product candidate for the treatment of acute kidney injury (AKI).

25 Oct 2012

Exploring the New Biopharmaceutical Contract Manufacturing Offering from Olympus

In this interview, News-Medical talks to Peter Gariepy, to find out about the new Contract Manufacturing Offering (CMO) from Olympus Life Science Solutions.

From Evident Corporation - Life Sciences 25 Oct 2012

BioLineRx intends to conduct interim analysis of BL-1020 Phase II/III trial for schizophrenia

BioLineRx, a biopharmaceutical development company, announced today that it intends to conduct an interim analysis of the Phase II/III CLARITY trial of BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia.

25 Oct 2012

New method of oral vaccination could help boost immunity to TB, influenza and C. difficile

Scientists at Royal Holloway, University of London have developed a pioneering new method of oral vaccination which could help boost immunity to TB and influenza, as well as prevent C. difficile for which there is currently no vaccine.

25 Oct 2012

Genzyme, Alnylam partner to develop and commercialize RNAi therapeutics against ATTR

Alnylam Pharmaceuticals, Inc. and Genzyme, a Sanofi company, announced today that they have formed an exclusive alliance to develop and commercialize RNAi therapeutics targeting transthyretin (TTR) for the treatment of transthyretin-mediated amyloidosis (ATTR) in Japan and other Asia-Pacific countries.

23 Oct 2012

Sickle cell disease treatments: An interview with Dr Niihara, CEO of Emmaus Medical

Sickle cell disease is a devastating hereditary condition that affects millions of people, particularly those in West and Central Africa as well as people of African descent in the United States, Europe and South America.

23 Oct 2012

Preclinical News and Research

Teva third quarter 2012 net revenues increase 14% to $5.0 billion

Omeros initiates enrollment in OMS824 Phase 1 trial for schizophrenia and Huntington's

Proposing standards and guidelines for Rett syndrome research

Isis announces preliminary data from ISIS-STAT3 Phase 1 study on cancer

Integra Holdings, a biopharmaceutical holding company, announced by Yissum

Development of children with ASD much like that of children without ASD at 6 months of age

Study finds two distinct patterns of language, social and motor development in children with ASD

BioCryst announces withdrawal of BCX5191 IND following discussion with FDA

Study finds two distinct patterns of language, social and motor development in children with ASD

Positive results from Celldex’s CDX-1401 Phase 1 study on solid tumors

Ultra-high performance SPECT systems announced by MILabs

Botanical treatment holds hope for triple-negative breast cancer

SAGE announces purchase of The Journal of International Medical Research

Highlights from 25th European College of Neuropsychopharmacology Congress

Thrasos completes $35 Million financing for development of THR-184 against AKI

Exploring the New Biopharmaceutical Contract Manufacturing Offering from Olympus

BioLineRx intends to conduct interim analysis of BL-1020 Phase II/III trial for schizophrenia

New method of oral vaccination could help boost immunity to TB, influenza and C. difficile

Genzyme, Alnylam partner to develop and commercialize RNAi therapeutics against ATTR

Sickle cell disease treatments: An interview with Dr Niihara, CEO of Emmaus Medical

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics